Clinical trials
catalyst calendar across sponsors →Studies where NPCE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 observational · 3 with posted results
Held by 12 tracked-famous managers (Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Man Group plc, +7 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| RNS System LGS Feasibility StudyNCT05339126Safety: Annual device-related serious adverse event (SADE) rateRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Device: RNS System | Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized | 24 | 2026-05-31 | 2026-01-12 |
| RNS System RESPONSE StudyNCT04839601Short-term chronic serious adverse device effect (SADE) rateOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Inadequate Enrollment | Device: RNS System | Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy | 9 | 2025-05-01actual | 2025-05-22 |
| RNS System NAUTILUS StudyNCT0514757112-week post-operative serious device-related adverse event (SADE) rateRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Responsive stimulation, Sham stimulation | Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure | 100 | 2025-04-04actual | 2026-06-08 |
| RNS® System Epilepsy Post-Approval StudyNCT02403843observationalSAE rate | — | Completed | Device: RNS System | Epilepsy | 345 | Dec 2023actual | 2026-04-09 |
| RNS® System LTT StudyNCT00572195results2019-06-26Number of Participants With Serious Adverse Events (SAE)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Device: RNS® System | Epilepsy | 230 | May 2018actual | 2019-06-26 |
| RNS® System Pivotal StudyNCT00264810results2013-08-28Acute SAE RateRandomized · Double-masked · Treatment | Phase 3 | Completed | Procedure: RNS® System implantation · Device: RNS® System responsive stimulation | Epilepsy | 240 | Oct 2009actual | 2013-08-28 |
| Study of an External Responsive Neurostimulator System on Epileptiform ActivityNCT00158067Non-randomized · Open-label · Treatment | Phase 2 | Completed | Device: external Responsive Neurostimulator (eRNS) System | Epilepsy | 150 | Apr 2007actual | 2010-08-26 |
| RNS® System Feasibility StudyNCT00079781results2013-12-24Acute SAE RateRandomized · Triple-masked · Treatment | Phase 2 | Completed | Procedure: RNS® System implantation · Device: RNS® System responsive stimulation | Epilepsy | 70 | May 2006actual | 2014-01-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19